Early warning indicators of HIV drug resistance in the southern highlands region of Tanzania: Lessons from a cross-sectional surveillance study

The World Health Organization early warning indicators (EWIs) permit surveillance of factors associated with the emergence of HIV drug resistance (HIVDR). We examined cross- and within-region performance on HIVDR EWIs for selected HIV care and treatment clinics (CTCs) in five regions of southern Tanzania. We retrospectively abstracted EWI data from 50 CTCs for the January to December 2013 period. EWIs included the following: on time ART pick-up, retention on ART, ARV stockouts, and pharmacy prescribing and dispensing practices. Data for pediatric and adult people living with HIV were abstracted from source files, and frequencies and proportions were calculated for each EWI overall, as well as stratified by region, facility, and age group. Across and within all regions, on average, on-time pick-up of pills (63.0%), retention on ART (76.0%), and pharmacy stockouts (69.0%) were consistently poor for the pediatric population. Similarly, on-time pill pick up (66.0%), retention on ART (72.0%) and pharmacy stockouts (53.0%) for adults were also poor. By contrast, performance on pharmacy prescribing and dispensing practices were as desired for both pediatric and adult populations with few facility-level exceptions. In this study, regions and facilities in the southern highlands of Tanzania reported widespread presence of HIVDR risk factors, including sub-optimal timeliness of pill pickup, retention on ART, and drug stockouts. There is an urgent need to implement the WHO EWIs monitoring to minimize the emergence of preventable HIV drug resistance and to maintain the effectiveness of first and second-line ART regimens. This is particularly critical in the context of new ART drug roll-out such as dolutegravir during the COVID-19 pandemic when resultant HIV service disruptions require careful monitoring, and for virologic suppression as countries move closer to epidemic control.

[1]  J. Livezey,et al.  Prevalence and Correlates of Viral Load Suppression and HIV Drug Resistance Among Children and Adolescents in South Rift Valley and Kisumu, Kenya. , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  E. Maina,et al.  Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya , 2021, Medicine.

[3]  C. Tseng,et al.  Multimonth dispensing of up to 6 months of antiretroviral therapy in Malawi and Zambia (INTERVAL): a cluster-randomised, non-blinded, non-inferiority trial. , 2021, The Lancet. Global health.

[4]  N. Rakhmanina,et al.  HIV Drug Resistance in Children and Adolescents: Always a Challenge? , 2021, Current Epidemiology Reports.

[5]  I. Scott,et al.  Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review , 2021, BMJ Open.

[6]  B. Mmbaga,et al.  “At home, no one knows”: A qualitative study of retention challenges among women living with HIV in Tanzania , 2020, PloS one.

[7]  S. Bhatt,et al.  Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study , 2020, The Lancet Global Health.

[8]  Benjamin R Phelps,et al.  Multimonth dispensing of antiretroviral therapy for HIV. , 2020, The lancet. HIV.

[9]  V. Colizzi,et al.  Programme quality indicators of HIV drug resistance among adolescents in urban versus rural settings of the centre region of Cameroon , 2020, AIDS Research and Therapy.

[10]  P. Kaleebu,et al.  Population-based monitoring of HIV drug resistance early warning indicators in Uganda: A nationally representative survey following revised WHO recommendations , 2020, PloS one.

[11]  N. Kiwanuka,et al.  Determinants of loss to follow-up among HIV positive patients receiving antiretroviral therapy in a test and treat setting: A retrospective cohort study in Masaka, Uganda , 2020, PloS one.

[12]  Y. Assefa,et al.  HIV drug resistance early warning indicators in Ethiopia: Variability at regional and health facility levels and trend over time. , 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[13]  P. Wekesa,et al.  Factors associated with 36-month loss to follow-up and mortality outcomes among HIV-infected adults on antiretroviral therapy in Central Kenya , 2019, BMC Public Health.

[14]  F. Kiweewa,et al.  “The number of clients is increasing but the supplies are reducing”: provider strategies for responding to chronic antiretroviral (ARV) medicines stock-outs in resource-limited settings: a qualitative study from Uganda , 2019, BMC Health Services Research.

[15]  D. Cooper,et al.  HIV treatment regimens and adherence to national guidelines in Australia: an analysis of dispensing data from the Australian pharmaceutical benefits scheme , 2019, BMC Public Health.

[16]  G. Rutherford,et al.  Supportive interventions to improve retention on ART in people with HIV in low- and middle-income countries: A systematic review , 2018, PloS one.

[17]  M. Egger,et al.  HIV drug resistance in sub-Saharan Africa: public health questions and the potential role of real-world data and mathematical modelling , 2018, Journal of virus eradication.

[18]  J. Matheka,et al.  Challenges to and opportunities for the adoption and routine use of early warning indicators to monitor pediatric HIV drug resistance in Kenya , 2018, BMC Pediatrics.

[19]  S. Iacob,et al.  Improving the Adherence to Antiretroviral Therapy, a Difficult but Essential Task for a Successful HIV Treatment—Clinical Points of View and Practical Considerations , 2017, Front. Pharmacol..

[20]  R. Murphy,et al.  Drug resistance patterns following pharmacy stock shortage in Nigerian Antiretroviral Treatment Program , 2017, AIDS Research and Therapy.

[21]  P. Mee,et al.  Identifying gaps in HIV policy and practice along the HIV care continuum: evidence from a national policy review and health facility surveys in urban and rural Kenya , 2017, Health policy and planning.

[22]  N. Dean,et al.  Assessment of the World Health Organization’s HIV Drug Resistance Early Warning Indicators in Main and Decentralized Outreach Antiretroviral Therapy Sites in Namibia , 2016, PloS one.

[23]  S. Oka,et al.  Effects of unplanned treatment interruptions on HIV treatment failure – results from TAHOD , 2016, Tropical medicine & international health : TM & IH.

[24]  S. Billong,et al.  Monitoring HIV Drug Resistance Early Warning Indicators in Cameroon: A Study Following the Revised World Health Organization Recommendations , 2015, PloS one.

[25]  A. Thorson,et al.  Antiretroviral treatment coverage in a rural district in Tanzania – a modeling study using empirical data , 2015, BMC Public Health.

[26]  M. Tanner,et al.  An assessment of the supply chain management for HIV/AIDS care and treatment in Kilombero and Ulanga districts in southern Tanzania , 2015 .

[27]  B. Kilama,et al.  Monitoring prevention or emergence of HIV drug resistance: results of a population-based foundational survey of early warning indicators in mainland Tanzania , 2014, BMC Infectious Diseases.

[28]  D. Pillay,et al.  Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis , 2012, The Lancet.

[29]  D. Bennett,et al.  HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.